vTv Therapeutics Inc. (VTVT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US9183852048
vTv Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -32.81 m USD |
| EBIT | -32.95 m USD |
| Net income | -26.97 m USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
More stocks
- Factorial Energy Inc. (FAC)
- HAVERTY FURNITURE COMPANIES INC (HVT)
- FACT II Acquisition Corp. (FACT)
- McKinley Acquisition Corp (MKLY)
- Yorkville Acquisition Corp. (MCGA)
- Digital Asset Acquisition Corp. (DAAQ)
- Plum Acquisition Corp, IV (PLMK)
- MARCHEX INC (MCHX)
- DAXOR CORP (DXR)
- BIMINI CAPITAL MANAGEMENT, INC. (BMNM)
- FARADAY FUTURE INTELLIGENT ELECTRIC INC. (FFAI)
- ALL THINGS MOBILE ANALYTIC, INC. (ATMH)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.